Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27392398 | 1.00 | HSD11B1 (0.37) | HSD11B1NR1H4NPC1TSHRRAB9A | |
| SCHEMBL30849257 | 0.83 | TSHR (0.40) | HSD11B1NR1H4NPC1TSHRRAB9A | |
| SCHEMBL27213684 | 0.82 | NR1H4 (0.40) | HSD11B1NR1H4 | |
| SCHEMBL27213825 | 0.80 | HSD11B1 (0.36) | HSD11B1NR1H4NPC1TSHRRAB9A | |
| SCHEMBL29318336 | 0.78 | SMO (0.37) | HSD11B1NR1H4 | |
| SCHEMBL30849280 | 0.76 | NR1H4 (0.34) | HSD11B1NR1H4NPC1TSHRRAB9A | |
| SCHEMBL27394436 | 0.75 | P2RX7 (0.39) | HSD11B1NR1H4 | |
| SCHEMBL27213713 | 0.72 | P2RX7 (0.39) | HSD11B1NR1H4 | |
| SCHEMBL30849221 | 0.72 | P2RX7 (0.39) | HSD11B1NR1H4 | |
| SCHEMBL27392402 | 0.72 | P2RX7 (0.39) | HSD11B1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024075051-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | HSD11B1 9/4885NR1H4 94/4885NPC1 999/4885 |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | HSD17B1, HSD17B3, HSD17B13 | HSD11B1 5/4885NR1H4 94/4885NPC1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.